Healthcare · Pharma · Life Sciences
From clinic floor to pharma launch, aesthetics campaign to specialty care. We work the commercial side of healthcare. Senior-led. In-house compliance. Skin in the game.
Where healthcare growth gets stuck
Pharma launches lose weeks to compliance review cycles. Clinic groups lose patients between primary contact and specialist appointment. Aesthetics brands compete for permission across overlapping channels. Specialty care depends on clinician trust earned over years.
Different operating realities, different constraints, different growth questions. The unifying frame across every healthcare engagement we run is the same: the patient is the only outcome that compounds.
We start with the diagnosis — what is actually limiting growth — before recommending anything. Across pharma, clinics, aesthetics, specialty care, and the brands that serve them, the diagnosis tells us where the leverage is.
Diagnosis is more than half the work. The plan is what follows.
What no other firm does
In standard pharma engagements, an external agency or consultancy produces creative, strategy, copy, or campaign work — and then submits it to the client's compliance officer. The work routinely gets shot down. Cycles consume weeks. Budgets burn on rejected creative. Launches slip.
This is structural, not a fault. The people doing the work and the people approving it do not share a regulatory frame.
At Dilogic, compliance review happens inside the firm before work leaves the building. Output reaches the pharma client already pre-cleared on the regulatory and compliance issues that would otherwise generate rejection cycles.
Fewer rounds. Faster shipping. Less budget burned.
Finding a partner with this kind of in-house regulatory function is rare across global agencies, consultancies, and boutiques. It is the result of a deliberate hire from a pharma background, integrated into a senior-led delivery model. It is hard to replicate, and it changes the economics of every launch we run.
Bigger picture
Strategy that connects market, brand, customer, channel, tech, and operations in one frame. In healthcare specifically, that means service-line mix, referral economics, payer dynamics, regulator constraints, and patient experience held together — not optimized one at a time.
Directed execution
Our network ships against the strategy: creative, media, marketing-ops build, brand identity, event production, and content production — all senior-led and vetted. We brief, we QA, we integrate. In pharma and biotech, the QA loop runs through our in-house compliance team first.
Accountable
A meaningful share of fees is tied to results — patients identified, leakage closed, launches landed, market entered. We do not bill for binders. We stay in the room until the results are showing.
What we do, in this sector
Six practices. Applied inside the regulators, payers, and clinical context of healthcare and life sciences.
Service-line strategy, geographic expansion, For pharma: launch sequencing, geography prioritization. For biotech commercial-stage: indication strategy, partnership models.
Read more →Patient acquisition, specialist referral leakage, payer partnerships, cross-border patient flow. For pharma: launches with the compliance moat accelerating the launch arc.
Read more →The patient journey across digital, telehealth, in-clinic, and post-care. The HCP engagement journey across digital, congress, and field.
Read more →Patient and brand experience moments. Event and exhibition strategy — Arab Health, Global Health Exhibition, therapy-area congresses.
Read more →The operating system marketing runs on, applied under patient-data and consent constraints. For pharma: every output pre-cleared by our in-house compliance team.
Read more →Patient-flow, billing-cycle, clinical-admin automation, specialty handoff workflows. Tech-led fixes that ship inside a quarter.
Read more →Buyer profile
The buyers we serve include CEOs and CSOs of private hospital and clinic groups; CMOs and brand leads at global pharma; pharma launch leads bringing new products to MENA; biotech founders and BD leaders preparing for commercial-stage; family office principals and PE operating partners deploying into healthcare.
Geographic anchor
GCC (UAE, Saudi Arabia, Qatar, Oman) · Levant (Egypt, Lebanon) · UK · Ireland, Italy, and the UK.
Out of scope
Clinical trial design. Biotech molecule strategy. Medtech device engineering. Pre-PMF healthtech startups. Businesses in turnaround.
Perspectives from the practice
Patient leakage
The leak is rarely where the dashboard says it is.
Read perspective →Pharma launches
The cycle-time math, with the case for restructuring before the next launch.
Read perspective →Biotech commercial
The pharma muscle every biotech needs by the time the FDA letter arrives.
Read perspective →Healthcare partner inbox
Patient identification. Compliance-cleared launches. Senior-led from the first conversation. Outcome-tied.
FAQ
